Barclays downgraded shares of Hologic (NASDAQ:HOLX) from an overweight rating to an equal weight rating in a report issued on Wednesday, The Fly reports. The firm currently has $43.00 price objective on the medical equipment provider’s stock, down from their previous price objective of $50.00. The analysts noted that the move was a valuation call.
Several other brokerages also recently issued reports on HOLX. TheStreet upgraded Hologic from a c rating to a b rating in a report on Tuesday, July 31st. BTIG Research reiterated a buy rating and set a $47.00 price target on shares of Hologic in a report on Thursday, August 2nd. Deutsche Bank upped their price target on Hologic from $42.00 to $45.00 and gave the stock a hold rating in a report on Wednesday, August 1st. BidaskClub upgraded Hologic from a sell rating to a hold rating in a research note on Friday, June 15th. Finally, Zacks Investment Research upgraded Hologic from a sell rating to a hold rating in a research note on Thursday, August 2nd. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and eight have assigned a buy rating to the stock. Hologic presently has a consensus rating of Hold and a consensus target price of $44.87.
Shares of Hologic stock opened at $39.04 on Wednesday. Hologic has a 12-month low of $35.10 and a 12-month high of $45.09. The firm has a market cap of $10.82 billion, a P/E ratio of 18.41, a P/E/G ratio of 1.81 and a beta of 0.65. The company has a quick ratio of 0.99, a current ratio of 1.29 and a debt-to-equity ratio of 1.12.
Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Tuesday, July 31st. The medical equipment provider reported $0.58 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.56 by $0.02. Hologic had a positive return on equity of 22.18% and a negative net margin of 2.47%. The business had revenue of $824.00 million during the quarter, compared to the consensus estimate of $800.14 million. equities analysts anticipate that Hologic will post 2.24 EPS for the current year.
A number of large investors have recently made changes to their positions in HOLX. Piedmont Investment Advisors LLC bought a new position in shares of Hologic during the 2nd quarter worth $127,000. Amussen Hunsaker Associates LLC bought a new position in shares of Hologic during the 2nd quarter worth $159,000. Synovus Financial Corp bought a new position in shares of Hologic during the 1st quarter worth $164,000. Homrich & Berg bought a new position in shares of Hologic during the 2nd quarter worth $204,000. Finally, Granite Springs Asset Management LLC bought a new position in shares of Hologic during the 2nd quarter worth $206,000. Hedge funds and other institutional investors own 98.66% of the company’s stock.
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Featured Story: NASDAQ
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.